All News
EULAR26: Pitfalls in Treat-to-Target
Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses.
Read Article
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
Read Article
No Fetal Risks with First Trimester NSAID Use
PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk.
Read Article
JAMA Review on Low Back Pain
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE. While the primary audience is generalists, the review carries important implications for rheumatologists who regularly encounter patients with back pain in the context of inflammatory arthritis, axial spondyloarthritis, and other systemic diseases.
Read Article
Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
CAR-T Cell Therapies at EULAR 2026
In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullin
Read Article
EULAR26 Insights into Gout and Obesity
New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied to higher diabetes and cardiovascular risk.
Read Article
Late-Breaking Studies at EULAR 2026
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc
Read Article
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12 recommendations.
Read Article
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.
Read Article
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
How many CAR-T’s do we need to test drive?
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Read Article
Lessons on Non-adherence
Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences in self-reported medication adherence and reasons for nonadherence across Type 1 & 2 SLE classification groups, with a prespecified focus on comparing the Mixed Activity group to all other groups.
Read Article
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Read Article
Jiha Lee JihaRheum ( View Tweet)
